Cited by 40Inflammatory Bowel DiseaseImmune Response and InflammationCytokine Signaling Pathways and Interactions

Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo

Open access
Ziesché, E, Scheiermann, P, Bachmann, M, Sadik, C D, Hofstetter, C, Zwissler, B, Pfeilschifter, J, Mühl, H·2009·Clinical and Experimental Immunology

Abstract

Summary: Interleukin (IL)-22 production triggered by innate immune mechanisms has been identified as key to efficient intestinal anti-bacterial host defence and preservation of homeostasis. We hypothesized that glucocorticoid therapy may impair IL-22 expression, which should promote intestinal epithelial damage with the potential of subsequent bacterial translocation. High-dose corticosteroid therapy in Crohn’s disease has been associated with an increased rate of abscess formation and ultimately with a higher risk of developing postoperative infectious complications, including abdominal sepsis. Thus, we sought to investigate effects of the prototypic glucocorticoid dexamethasone on IL-22 production in the context of bacterial infection. Enhanced IL-22 plasma levels were detectable in rat sepsis. Moreover, heat-inactivated Staphylococcus epidermidis, used as a prototypic activator of innate immunity, induced robust production of IL-22 by human peripheral blood mononuclear cells (PBMC). Here, we report for the first time that dexamethasone mediates remarkable suppression of IL-22 as detected in S. epidermidis-activated PBMC and rat sepsis, respectively. The data presented herein suggest that insufficient IL-22 function may contribute to impaired intestinal host defence in the context of corticosteroid therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2249.2009.03969.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Systemic use of dexamethasone can cause serious side-effects by depressing the innate immune response and increasing infection likelihood.

    “systemic use of DX can cause serious side-effects by depressing the innate immune response, thus increasing the likelihood of infection.178–179”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ziesché, E., Scheiermann, P., Bachmann, M., Sadik, C. D., Hofstetter, C., Zwissler, B., Pfeilschifter, J., & Mühl, H.
Affiliations
  • Goethe University Frankfurt (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • Pharmazentrum Frankfurt/ZAFES
Corresponding author
Mühl, H
Venue
Clinical and Experimental Immunology
Published
2009-05-06
Volume
157
Issue
3
Pages
370-376
ISSN
  • 0009-9104 (ISSN-L)
  • 1365-2249
OpenAlex
W1540737922
Cited by
40
References
34
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 4 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 5 · 2013: 5 · 2012: 4
FWCI
1.75
Type
journal article
Language
en
Open access
Locations
  • Clinical & Experimental Immunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
Keywords
dexamethasone, IL-22, glucocorticoids, bacterial infection, sepsis, Staphylococcus epidermidis, innate immunity, Crohn's disease, corticosteroid therapy, bacterial translocation, peripheral blood mononuclear cells, intestinal epithelial damage
MeSH terms
Interleukin-22, Animals, Cells, Cultured, Depression, Chemical, Dexamethasone, Glucocorticoids, Humans, Interleukins, Male, Peritonitis, Random Allocation, RNA, Messenger, Staphylococcal Infections, Staphylococcus epidermidis, Gene Expression, Case-Control Studies, Interleukin-8, Interleukin-10, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Models, Animal, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review